Home Healthcare Biotechnology Immunoglobulins Market

Immunoglobulins Market Size, Share & Trends Analysis Report By Product (IgG, IgA, IgM, IgE, IgD), By Mode of Delivery (Intravenous Mode of Delivery, Subcutaneous Mode of Delivery), By Application (Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: April 29, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Immunoglobulins Market, By Product 2022-2034 (USD MILLION/ Units)
    1. IgG
    2. IgA
    3. IgM
    4. IgE
    5. IgD
  2. Immunoglobulins Market, By Mode of Delivery 2022-2034 (USD MILLION/ Units)
    1. Intravenous Mode of Delivery
    2. Subcutaneous Mode of Delivery
  3. Immunoglobulins Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Hypogammaglobulinemia
    2. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
    3. Immunodeficiency Disease
    4. Myasthenia Gravis
  4. Regional Immunoglobulins Market
    1. North America
      1. North America Immunoglobulins Market By Product 2022-2034 (USD MILLION/ Units)
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
      2. North America Immunoglobulins Market By Mode of Delivery 2022-2034 (USD MILLION/ Units)
        1. Intravenous Mode of Delivery
        2. Subcutaneous Mode of Delivery
      3. North America Immunoglobulins Market By Application 2022-2034 (USD MILLION/ Units)
        1. Hypogammaglobulinemia
        2. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        3. Immunodeficiency Disease
        4. Myasthenia Gravis
      4. U.S.
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      5. Canada
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
    2. Europe
      1. Europe Immunoglobulins Market By Product 2022-2034 (USD MILLION/ Units)
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
      2. Europe Immunoglobulins Market By Mode of Delivery 2022-2034 (USD MILLION/ Units)
        1. Intravenous Mode of Delivery
        2. Subcutaneous Mode of Delivery
      3. Europe Immunoglobulins Market By Application 2022-2034 (USD MILLION/ Units)
        1. Hypogammaglobulinemia
        2. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        3. Immunodeficiency Disease
        4. Myasthenia Gravis
      4. U.K.
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      5. Germany
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      6. France
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      7. Spain
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      8. Italy
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      9. Russia
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      10. Nordic
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      11. Benelux
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      12. Rest of Europe
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
    3. APAC
      1. APAC Immunoglobulins Market By Product 2022-2034 (USD MILLION/ Units)
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
      2. APAC Immunoglobulins Market By Mode of Delivery 2022-2034 (USD MILLION/ Units)
        1. Intravenous Mode of Delivery
        2. Subcutaneous Mode of Delivery
      3. APAC Immunoglobulins Market By Application 2022-2034 (USD MILLION/ Units)
        1. Hypogammaglobulinemia
        2. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        3. Immunodeficiency Disease
        4. Myasthenia Gravis
      4. China
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      5. Korea
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      6. Japan
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      7. India
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      8. Australia
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      9. Taiwan
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      10. South East Asia
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      11. Rest of Asia-Pacific
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
    4. Middle East and Africa
      1. Middle East and Africa Immunoglobulins Market By Product 2022-2034 (USD MILLION/ Units)
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
      2. Middle East and Africa Immunoglobulins Market By Mode of Delivery 2022-2034 (USD MILLION/ Units)
        1. Intravenous Mode of Delivery
        2. Subcutaneous Mode of Delivery
      3. Middle East and Africa Immunoglobulins Market By Application 2022-2034 (USD MILLION/ Units)
        1. Hypogammaglobulinemia
        2. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        3. Immunodeficiency Disease
        4. Myasthenia Gravis
      4. UAE
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      5. Turkey
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      6. Saudi Arabia
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      7. South Africa
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      8. Egypt
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      9. Nigeria
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      10. Rest of MEA
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
    5. LATAM
      1. LATAM Immunoglobulins Market By Product 2022-2034 (USD MILLION/ Units)
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
      2. LATAM Immunoglobulins Market By Mode of Delivery 2022-2034 (USD MILLION/ Units)
        1. Intravenous Mode of Delivery
        2. Subcutaneous Mode of Delivery
      3. LATAM Immunoglobulins Market By Application 2022-2034 (USD MILLION/ Units)
        1. Hypogammaglobulinemia
        2. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        3. Immunodeficiency Disease
        4. Myasthenia Gravis
      4. Brazil
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      5. Mexico
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      6. Argentina
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      7. Chile
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      8. Colombia
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
      9. Rest of LATAM
        1. IgG
        2. IgA
        3. IgM
        4. IgE
        5. IgD
        6. Intravenous Mode of Delivery
        7. Subcutaneous Mode of Delivery
        8. Hypogammaglobulinemia
        9. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        10. Immunodeficiency Disease
        11. Myasthenia Gravis
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.